KARDİYOVASKÜLER SİSTEM HASTALIKLARINDA KULLANILAN İLAÇLAR İLE ENDODONTİDE SİSTEMİK OLARAK KULLANILAN İLAÇLAR ARASINDAKİ İLAÇ ETKİLEŞİMLERİ

Gökhan Saygılı; Hüseyin Ertaş; Hakan Arslan; Yusuf Cem Kaplan; Elif Tarım Ertaş; İsmail Davut Çapar

KARDİYOVASKÜLER SİSTEM HASTALIKLARINDA KULLANILAN İLAÇLAR İLE ENDODONTİDE SİSTEMİK OLARAK KULLANILAN İLAÇLAR ARASINDAKİ İLAÇ ETKİLEŞİMLERİ

Year 2014, Volume: 23 Issue: 1, 38 - 46, 01.03.2014

Gökhan Saygılı Hüseyin Ertaş Hakan Arslan Yusuf Cem Kaplan Elif Tarım Ertaş İsmail Davut Çapar

Abstract

Keywords

Analjezik, antibiyotik, endodonti, ilaç etkileşimi, kardiyovasküler hastalıklar, kök kanal tedavisi, sistemik diş hekimliği

References

1. Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255- 1259.
2. Onat A, Ugur M, Cicek G, ve ark. Kırsal kesim ve kentlerde benzer kardiyovaskü ler ölü m riski. Tü rk Kardiyol Dern Arş 2010; 38: 159-163.
3. Arslan S, Atalay A, Kutsal Y. Yaşlılarda ilaç kullanımı. Geriatri 2000; 3: 56-60.
4. Ingle JI, Glick DH. Different diagnosıs and treatment of dental pain. In: Ingle JI, Taintor FC (eds). Endodontics. (3rd ed), Philadelphia, Lea & Febiger 1985; pp 288-289.
5. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-306.
6. Levy M, Kewitz H, Altwein W, et al. Hospital admissions due to adverse drug reactions: A comparative study from Jerusalem and Berlin. Eur J Clin Pharmacol 1980; 17: 25-31.
7. Schneeweiss S, Hasford J, Gottler M, et al. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol 2002; 58: 285-291.
8. van der Hooft CS, Sturkenboom MC, van Grootheest K, et al. Adverse drug reaction- related hospitalisations: A nationwide study in The Netherlands. Drug Saf 2006; 29: 161-168.
9. Fuhr U. Improvement in the handling of drug-drug interactions. Eur J Clin Pharmacol 2008; 64: 167-171.
10. Delpó n E GCF. Fá rmacos antiarrı́tmicos. En: Tamargo J. (coord). Farmacologı́a cardiovascular. Acció n Médica 2009; pp. 15- 38.
13. Singh BN, Vaughan Williams EM. A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 1970; 39: 675-687.
14. Cazzola M, Blasi F, Ewig S. Antibiotics and the Lung. European Respiratory Society Monograph (Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections) 2004; 28: 229-254.
15. Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001; 18: S71-S76
17. Paar D, Terjung B, Sauerbruch T. Life- threatening interaction between clarithromycin and disopyramide. Lancet 1997; 349: 326-327.
18. Henneman A, Thornby KA. Risk of hypotension with concomitant use of calcium- channel blockers and macrolide antibiotics. Am J Health Syst Pharm 2012; 69: 1038-1043.
19. Wright AJ, Gomes T, Mamdani MM, et al. The risk of hypotension following co- prescription of macrolide antibiotics and calcium-channel blockers. CMAJ 2011; 183: 303-307.
21. Wolff K, Rostami-Hodjegan A, Hay AW, et al. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 2000; 95: 1771-1783.
23. Lakshman D, Simon C, Ursula C, et al. Adverse drug interactions: a handbook for prescribers. Br J Clin Pharmacol 2011; 71: 301-302.
26. Rice PJ, Perry RJ, Afzal Z, et al. Antibacterial prescribing and warfarin: A review. Br Dent J 2003; 194: 411-415.
27. Conly J, Stein K. Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials. Clin Invest Med 1994; 17: 531-539.
28. Brown M A KED, Miller D R. Interaction of penicillin-G and warfarin. Can J Hosp Pharm 1979; 32: 18-19.
29. Hylek EM. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatr Med 2001; 17: 1-13.
31. Zhang Q, Simoneau G, Verstuyft C, et al. Amoxicillin/clavulanic acid-warfarin drug interaction: A randomized controlled trial. Br J Clin Pharmacol 2011; 71: 232-236.
33. Turck D, Su CA, Heinzel G, et al. Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol 1997; 51: 421-425.
34. Anon.Pharmacologıcal management of persistent Pain in older persons. American Geriatry Society 2009; 57: 1331-1346.
35. Shalansky S, Lynd L, Richardson K, et al. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy 2007; 27: 1237-1247.
36. Launiainen T, Sajantila A, Rasanen I, et al. Adverse interaction of warfarin and paracetamol: Evidence from a post-mortem study. Eur J Clin Pharmacol 2010; 66: 97- 103.
37. Parra D, Beckey NP, Stevens GR. The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy. Pharmacotherapy 2007; 27: 675-683.
38. Antlitz AM, Awalt LF. A double blind study of acetaminophen used in conjunction with oral anticoagulant therapy. Curr Ther Res Clin Exp 1969; 11: 360-361.
39. Mahe I, Bertrand N, Drouet L, et al. Interaction between paracetamol and warfarin in patients: A double-blind, placebo- controlled, randomized study. Haematologica 2006; 91: 1621-1627.
40. Lopes RD, Horowitz JD, Garcia DA, et al. Warfarin and acetaminophen interaction: A summary of the evidence and biologic plausibility. Blood 2011; 118: 6269-6273.
41. Passmore AP, Crawford VLS, Beringer TRO, et al. Determinants of drug utilisation in an elderly population in North and West Belfast. Pharmacoepidemiol Drug Saf 1995; 4: 147-160.
42. Andrew P, Ten Eick DS, Tamar Preminger, et al. Possible drug interaction between digoxin and azithromycin in a young child.Clin Drug Invest 2000 2000; 20: 61- 64.
43. Nawarskas JJ, McCarthy DM, Spinler SA. Digoxin toxicity secondary to clarithromycin therapy. Ann Pharmacother 1997; 31: 864-866.
44. Zand F, Asadi S, Katibeh P. Good outcome after digoxin toxicity despite very high serum potassium level. Iran Red Crescent Med J 2011; 13: 680-681.
45. Lee CYW, Marcotte F, Giraldeau G, et al. Digoxin toxicity precipitated by clarithromycin use: Case presentation and review of the literature. Canadian Journal of Cardiology 2011; 27: 870, e15-16.
46. Aronow WS, Frishman WH, Cheng-Lai A. Cardiovascular drug therapy in the elderly. Cardiol Rev 2007; 15: 195-215.
47. Finch MB, Johnston GD, Kelly JG, McDevitt DG. Pharmacokinetics of digoxin alone and in the presence of indomethacin therapy. Br J Clin Pharmacol 1984; 17: 353- 355.
48. Jorgensen HS, Christensen HR, Kampmann JP. Interaction between digoxin and indomethacin or ibuprofen. Br J Clin Pharmacol 1991; 31: 108-110.
49. Nadeem A, Allegretti P. Blurred vision and weakness in a 60-year-old woman. Am J Emerg Med 2010; 28: 536, e1-2.
50. Davies NM. Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo- oxygenase-2 inhibition? Clin Pharmacokinet 1997; 33: 404-416.
51. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513- 1518.
52. Benowitz B. Basic and Clinical Pharmacology, Appleton and Lange 1998; pp 253- 257.
53. Laurence DR, Bennet P. Clinical Pharmacology. Churchill Livingstone, England 1992; pp 249-260
59. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504-2510.
60. Chalmers JP, West MJ, Wing LM, et al. Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clin Exp Hypertens A 1984; 6: 1077-1093.
62. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
63. Lakshman D, Karalleidde SFJC, Ursula C, et al. Adverse Drug Interactions: A Handbook for Prescribers. Taylor and Francis Group, UK,2010; pp 477-478.
64. Anon. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death MI, and stroke in high risk patients. Br Med J 2002; 324: 71-86
66. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Eng J Med 2003; 348: 891-899.
68. Cataldo G, Heiman F, Lavezzari M, et al. Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery: Results of a combined analysis. Coron Artery Dis 1998; 9: 217-222.
69. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644.
71. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-574.
72. Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med 2001; 110: S28-S32.
79. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet 2004; 364: 665-674.
81. FDA. Drug Interactions: What You Should Know? http://www.fda.gov/drugs/ resourcesforyou/ucm 163354.htm (Erişim Tarihi: 03/03/2014)

DRUG INTERACTIONS BETWEEN DRUGS USED IN CARDIOVASCULAR SYSTEM DISEASES AND DRUGS USED IN ENDODONTIC TREATMENT SYSTEMATICALLY

Year 2014, Volume: 23 Issue: 1, 38 - 46, 01.03.2014

Gökhan Saygılı Hüseyin Ertaş Hakan Arslan Yusuf Cem Kaplan Elif Tarım Ertaş İsmail Davut Çapar

Abstract

During endodontic treatment various drugs could be prescribed to the patients with cardiovascular diseases. These prescribed drugs could be used together with the drugs which has already used by the patient. Combined use of two drugs can cause drug interactions as well as other drug reactions. The aim of this review is to provide information on drug interactions between drugs used in cardiovascular system diseases and drugs used in endodontic treatment systematically

Keywords

Analgesic, antibiotics, endodontics, drug interaction, cardiovascular diseases, root canal therapy, systemic dentistry

References

1. Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255- 1259.
2. Onat A, Ugur M, Cicek G, ve ark. Kırsal kesim ve kentlerde benzer kardiyovaskü ler ölü m riski. Tü rk Kardiyol Dern Arş 2010; 38: 159-163.
3. Arslan S, Atalay A, Kutsal Y. Yaşlılarda ilaç kullanımı. Geriatri 2000; 3: 56-60.
4. Ingle JI, Glick DH. Different diagnosıs and treatment of dental pain. In: Ingle JI, Taintor FC (eds). Endodontics. (3rd ed), Philadelphia, Lea & Febiger 1985; pp 288-289.
5. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-306.
6. Levy M, Kewitz H, Altwein W, et al. Hospital admissions due to adverse drug reactions: A comparative study from Jerusalem and Berlin. Eur J Clin Pharmacol 1980; 17: 25-31.
7. Schneeweiss S, Hasford J, Gottler M, et al. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol 2002; 58: 285-291.
8. van der Hooft CS, Sturkenboom MC, van Grootheest K, et al. Adverse drug reaction- related hospitalisations: A nationwide study in The Netherlands. Drug Saf 2006; 29: 161-168.
9. Fuhr U. Improvement in the handling of drug-drug interactions. Eur J Clin Pharmacol 2008; 64: 167-171.
10. Delpó n E GCF. Fá rmacos antiarrı́tmicos. En: Tamargo J. (coord). Farmacologı́a cardiovascular. Acció n Médica 2009; pp. 15- 38.
13. Singh BN, Vaughan Williams EM. A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 1970; 39: 675-687.
14. Cazzola M, Blasi F, Ewig S. Antibiotics and the Lung. European Respiratory Society Monograph (Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections) 2004; 28: 229-254.
15. Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001; 18: S71-S76
17. Paar D, Terjung B, Sauerbruch T. Life- threatening interaction between clarithromycin and disopyramide. Lancet 1997; 349: 326-327.
18. Henneman A, Thornby KA. Risk of hypotension with concomitant use of calcium- channel blockers and macrolide antibiotics. Am J Health Syst Pharm 2012; 69: 1038-1043.
19. Wright AJ, Gomes T, Mamdani MM, et al. The risk of hypotension following co- prescription of macrolide antibiotics and calcium-channel blockers. CMAJ 2011; 183: 303-307.
21. Wolff K, Rostami-Hodjegan A, Hay AW, et al. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 2000; 95: 1771-1783.
23. Lakshman D, Simon C, Ursula C, et al. Adverse drug interactions: a handbook for prescribers. Br J Clin Pharmacol 2011; 71: 301-302.
26. Rice PJ, Perry RJ, Afzal Z, et al. Antibacterial prescribing and warfarin: A review. Br Dent J 2003; 194: 411-415.
27. Conly J, Stein K. Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials. Clin Invest Med 1994; 17: 531-539.
28. Brown M A KED, Miller D R. Interaction of penicillin-G and warfarin. Can J Hosp Pharm 1979; 32: 18-19.
29. Hylek EM. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatr Med 2001; 17: 1-13.
31. Zhang Q, Simoneau G, Verstuyft C, et al. Amoxicillin/clavulanic acid-warfarin drug interaction: A randomized controlled trial. Br J Clin Pharmacol 2011; 71: 232-236.
33. Turck D, Su CA, Heinzel G, et al. Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol 1997; 51: 421-425.
34. Anon.Pharmacologıcal management of persistent Pain in older persons. American Geriatry Society 2009; 57: 1331-1346.
35. Shalansky S, Lynd L, Richardson K, et al. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy 2007; 27: 1237-1247.
36. Launiainen T, Sajantila A, Rasanen I, et al. Adverse interaction of warfarin and paracetamol: Evidence from a post-mortem study. Eur J Clin Pharmacol 2010; 66: 97- 103.
37. Parra D, Beckey NP, Stevens GR. The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy. Pharmacotherapy 2007; 27: 675-683.
38. Antlitz AM, Awalt LF. A double blind study of acetaminophen used in conjunction with oral anticoagulant therapy. Curr Ther Res Clin Exp 1969; 11: 360-361.
39. Mahe I, Bertrand N, Drouet L, et al. Interaction between paracetamol and warfarin in patients: A double-blind, placebo- controlled, randomized study. Haematologica 2006; 91: 1621-1627.
40. Lopes RD, Horowitz JD, Garcia DA, et al. Warfarin and acetaminophen interaction: A summary of the evidence and biologic plausibility. Blood 2011; 118: 6269-6273.
41. Passmore AP, Crawford VLS, Beringer TRO, et al. Determinants of drug utilisation in an elderly population in North and West Belfast. Pharmacoepidemiol Drug Saf 1995; 4: 147-160.
42. Andrew P, Ten Eick DS, Tamar Preminger, et al. Possible drug interaction between digoxin and azithromycin in a young child.Clin Drug Invest 2000 2000; 20: 61- 64.
43. Nawarskas JJ, McCarthy DM, Spinler SA. Digoxin toxicity secondary to clarithromycin therapy. Ann Pharmacother 1997; 31: 864-866.
44. Zand F, Asadi S, Katibeh P. Good outcome after digoxin toxicity despite very high serum potassium level. Iran Red Crescent Med J 2011; 13: 680-681.
45. Lee CYW, Marcotte F, Giraldeau G, et al. Digoxin toxicity precipitated by clarithromycin use: Case presentation and review of the literature. Canadian Journal of Cardiology 2011; 27: 870, e15-16.
46. Aronow WS, Frishman WH, Cheng-Lai A. Cardiovascular drug therapy in the elderly. Cardiol Rev 2007; 15: 195-215.
47. Finch MB, Johnston GD, Kelly JG, McDevitt DG. Pharmacokinetics of digoxin alone and in the presence of indomethacin therapy. Br J Clin Pharmacol 1984; 17: 353- 355.
48. Jorgensen HS, Christensen HR, Kampmann JP. Interaction between digoxin and indomethacin or ibuprofen. Br J Clin Pharmacol 1991; 31: 108-110.
49. Nadeem A, Allegretti P. Blurred vision and weakness in a 60-year-old woman. Am J Emerg Med 2010; 28: 536, e1-2.
50. Davies NM. Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo- oxygenase-2 inhibition? Clin Pharmacokinet 1997; 33: 404-416.
51. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513- 1518.
52. Benowitz B. Basic and Clinical Pharmacology, Appleton and Lange 1998; pp 253- 257.
53. Laurence DR, Bennet P. Clinical Pharmacology. Churchill Livingstone, England 1992; pp 249-260
59. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504-2510.
60. Chalmers JP, West MJ, Wing LM, et al. Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clin Exp Hypertens A 1984; 6: 1077-1093.
62. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
63. Lakshman D, Karalleidde SFJC, Ursula C, et al. Adverse Drug Interactions: A Handbook for Prescribers. Taylor and Francis Group, UK,2010; pp 477-478.
64. Anon. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death MI, and stroke in high risk patients. Br Med J 2002; 324: 71-86
66. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Eng J Med 2003; 348: 891-899.
68. Cataldo G, Heiman F, Lavezzari M, et al. Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery: Results of a combined analysis. Coron Artery Dis 1998; 9: 217-222.
69. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644.
71. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-574.
72. Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med 2001; 110: S28-S32.
79. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet 2004; 364: 665-674.
81. FDA. Drug Interactions: What You Should Know? http://www.fda.gov/drugs/ resourcesforyou/ucm 163354.htm (Erişim Tarihi: 03/03/2014)

There are 56 citations in total.

Details

Other ID	JA65RB22AS
Journal Section	Research Article
Authors	Gökhan Saygılı This is me Hüseyin Ertaş This is me Hakan Arslan This is me Yusuf Cem Kaplan This is me Elif Tarım Ertaş This is me İsmail Davut Çapar This is me
Publication Date	March 1, 2014
Submission Date	March 1, 2014
Published in Issue	Year 2014 Volume: 23 Issue: 1

Cite

APA	Saygılı, G., Ertaş, H., Arslan, H., Kaplan, Y. C., et al. (2014). KARDİYOVASKÜLER SİSTEM HASTALIKLARINDA KULLANILAN İLAÇLAR İLE ENDODONTİDE SİSTEMİK OLARAK KULLANILAN İLAÇLAR ARASINDAKİ İLAÇ ETKİLEŞİMLERİ. Sağlık Bilimleri Dergisi, 23(1), 38-46.
AMA	Saygılı G, Ertaş H, Arslan H, Kaplan YC, Tarım Ertaş E, Çapar İD. KARDİYOVASKÜLER SİSTEM HASTALIKLARINDA KULLANILAN İLAÇLAR İLE ENDODONTİDE SİSTEMİK OLARAK KULLANILAN İLAÇLAR ARASINDAKİ İLAÇ ETKİLEŞİMLERİ. JHS. March 2014;23(1):38-46.
Chicago	Saygılı, Gökhan, Hüseyin Ertaş, Hakan Arslan, Yusuf Cem Kaplan, Elif Tarım Ertaş, and İsmail Davut Çapar. “KARDİYOVASKÜLER SİSTEM HASTALIKLARINDA KULLANILAN İLAÇLAR İLE ENDODONTİDE SİSTEMİK OLARAK KULLANILAN İLAÇLAR ARASINDAKİ İLAÇ ETKİLEŞİMLERİ”. Sağlık Bilimleri Dergisi 23, no. 1 (March 2014): 38-46.
EndNote	Saygılı G, Ertaş H, Arslan H, Kaplan YC, Tarım Ertaş E, Çapar İD (March 1, 2014) KARDİYOVASKÜLER SİSTEM HASTALIKLARINDA KULLANILAN İLAÇLAR İLE ENDODONTİDE SİSTEMİK OLARAK KULLANILAN İLAÇLAR ARASINDAKİ İLAÇ ETKİLEŞİMLERİ. Sağlık Bilimleri Dergisi 23 1 38–46.
IEEE	G. Saygılı, H. Ertaş, H. Arslan, Y. C. Kaplan, E. Tarım Ertaş, and İ. D. Çapar, “KARDİYOVASKÜLER SİSTEM HASTALIKLARINDA KULLANILAN İLAÇLAR İLE ENDODONTİDE SİSTEMİK OLARAK KULLANILAN İLAÇLAR ARASINDAKİ İLAÇ ETKİLEŞİMLERİ”, JHS, vol. 23, no. 1, pp. 38–46, 2014.
ISNAD	Saygılı, Gökhan et al. “KARDİYOVASKÜLER SİSTEM HASTALIKLARINDA KULLANILAN İLAÇLAR İLE ENDODONTİDE SİSTEMİK OLARAK KULLANILAN İLAÇLAR ARASINDAKİ İLAÇ ETKİLEŞİMLERİ”. Sağlık Bilimleri Dergisi 23/1 (March 2014), 38-46.
JAMA	Saygılı G, Ertaş H, Arslan H, Kaplan YC, Tarım Ertaş E, Çapar İD. KARDİYOVASKÜLER SİSTEM HASTALIKLARINDA KULLANILAN İLAÇLAR İLE ENDODONTİDE SİSTEMİK OLARAK KULLANILAN İLAÇLAR ARASINDAKİ İLAÇ ETKİLEŞİMLERİ. JHS. 2014;23:38–46.
MLA	Saygılı, Gökhan et al. “KARDİYOVASKÜLER SİSTEM HASTALIKLARINDA KULLANILAN İLAÇLAR İLE ENDODONTİDE SİSTEMİK OLARAK KULLANILAN İLAÇLAR ARASINDAKİ İLAÇ ETKİLEŞİMLERİ”. Sağlık Bilimleri Dergisi, vol. 23, no. 1, 2014, pp. 38-46.
Vancouver	Saygılı G, Ertaş H, Arslan H, Kaplan YC, Tarım Ertaş E, Çapar İD. KARDİYOVASKÜLER SİSTEM HASTALIKLARINDA KULLANILAN İLAÇLAR İLE ENDODONTİDE SİSTEMİK OLARAK KULLANILAN İLAÇLAR ARASINDAKİ İLAÇ ETKİLEŞİMLERİ. JHS. 2014;23(1):38-46.

Article Files

Full Text